^
    2d
    Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer. (PubMed, Clin Breast Cancer)
    A DE approach to abemaciclib was associated with significantly fewer treatment interruptions and dose reductions while maintaining similar discontinuation rates compared with SD. These findings suggest that DE may improve early tolerability, support treatment adherence, and optimize clinical outcomes in high-risk HR+, HER2-, EBC patients.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Verzenio (abemaciclib)
    2d
    Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer. (PubMed, Clin Ther)
    This comprehensive ethnicity assessment suggests comparable PK of ribociclib between Asian and non-Asian patients and supports current dose recommendations in Asian patients.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib)
    2d
    Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo. (PubMed, Cancer Chemother Pharmacol)
    Our findings suggest that clinically significant OATP1B-mediated interactions are not anticipated with CDK4/6 inhibitors, either as victims or perpetrators, which supports ongoing clinical trials investigating the co-administration of CDK4/6 inhibitors with OATP1B substrates and inhibitors.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Kisqali (ribociclib) • simvastatin
    2d
    Tumor-suppressive role of miR-216b impacts cell cycle regulation in high-grade glioma. (PubMed, Acta Neuropathol Commun)
    In addition, miR-216b expression correlated with increased sensitivity to the CDK4/6 inhibitor Abemaciclib...The observed results support the potential of miR-216b as both a prognostic and predictive indicator in HGGs. The online version contains supplementary material available at 10.1186/s40478-025-02215-5.
    Journal • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    IDH wild-type
    |
    Verzenio (abemaciclib)
    2d
    TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy (clinicaltrials.gov)
    P1, N=78, Recruiting, Tasly Pharmaceutical Group Co., Ltd
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HER-2 negative + ER positive
    2d
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    2d
    LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy (clinicaltrials.gov)
    P1/2, N=12, Completed, Georgetown University | N=44 --> 12 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    |
    everolimus • Kisqali (ribociclib)
    3d
    A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=480, Completed, Novartis Pharmaceuticals
    New trial • HEOR • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    5d
    Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates. (PubMed, Breast)
    Optimized staging and risk assessment in HR+/HER2- EBC is critical to identify high-risk patients eligible for CDK4/6 inhibitors. Implementing these recommendations may improve patient outcomes in the adjuvant setting.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib)
    6d
    Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Hubei Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HR positive
    |
    Verzenio (abemaciclib)
    7d
    Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature. (PubMed, Front Med (Lausanne))
    Entecavir antiviral therapy led to suppressed viral replication and improved liver function during follow-up. This case emphasizes the need for HBV screening and close monitoring of viral markers/liver function in asymptomatic HBV carriers receiving dalpiciclib, as early antiviral intervention prevents severe liver complications. It also highlights the importance of clinical pharmacist-led medication follow-up management for outpatients receiving targeted anticancer therapy to avoid oversight of comorbidities and associated prophylactic treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    AiRuiKang (dalpiciclib)
    7d
    Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth. (PubMed, bioRxiv)
    Mirdametinib and abemaciclib combined to extend survival of mice bearing orthotopic ATRT xenografts. In conclusion, mirdametinib has single agent activity against ATRT and combines with abemaciclib to decrease proliferation and extend survival in orthotopic xenograft models of ATRT.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Verzenio (abemaciclib) • Gomekli (mirdametinib)